Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of CD5 CAR-T for Refractory/Relapsed CD5+ T-ALL Patients

NCT05596266 is registered in ClinicalTrials.gov with Xuanwu Hospital, Beijing as lead sponsor.

NCT NCT05596266
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05596266 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of CD5 CAR-T for Refractory/Relapsed CD5+ T-ALL Patients
Lead sponsor
Xuanwu Hospital, Beijing
Phase
Phase 1
Overall status
Unknown status
Start date
October 25, 2022
Completion date
October 25, 2025
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

t-cell acute lymphoblastic leukemia